Patients with Lung Cancer and end-stage renal failure undergoing HD
Conditions
Interventions
None listed
Sponsors
Chiba University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The following cases meeting criteria 1) and 2) are eligible. 1) Cases treated with CDDP+ETP for advanced or recurrent lung cancer between January 2000 and December 2024. Cases previously treated with single-agent molecularly targeted therapy or single-agent immune checkpoint inhibitor therapy are eligible. 2) Cases undergoing maintenance hemodialysis prior to initiation of chemotherapy for end-stage renal failure. * Both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are included. * Cases treated with chemoradiotherapy will be included for adverse event collection but excluded from overall survival data.
Exclusion criteria
Exclusion criteria: Exclude cases meeting any of the following criteria: 1) Cases with cancer of unknown primary origin or cases receiving chemotherapy for malignant tumors other than lung cancer 2) Cases receiving chemotherapy for cancers other than lung cancer within six months prior to initiation of CDDP+ETP therapy 3) Cases requiring dialysis after starting chemotherapy for lung cancer 4) Cases receiving combination therapy with molecularly targeted drugs or immune checkpoint inhibitors alongside CDDP+ETP 5) Individuals who expressed refusal to participate in this study through the information disclosure document.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of non-hematologic toxicities of grade 3 or higher and hematologic toxicities of grade 4 or higher | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate, progression free survival, overall survival, frequency of patients discontinued or delayed due to adverse events. | — |
Countries
Japan
Contacts
Public ContactMikihito Saito
Chiba University Hospital Department of Respirology
Outcome results
None listed